Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 known ✓ | P21453 | 2/20 | 0.34 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.33 |
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.33 |
| ▸ | S1PR4 known ✓ | O95977 | 1/20 | 0.32 |
| ▸ | S1PR3 known ✓ | Q99500 | 1/20 | 0.32 |
| ▸ | S1PR5 known ✓ | Q9H228 | 1/20 | 0.32 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.39 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYSLTR2 | Q9NS75 | 2/20 | 0.33 |
| ▸ | CYSLTR1 | Q9Y271 | 2/20 | 0.33 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.33 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.33 |
| ▸ | TYR | P14679 | 1/20 | 0.33 |
| ▸ | SGPL1 | O95470 | 1/20 | 0.32 |
| ▸ | GPR183 | P32249 | 1/20 | 0.32 |
| ▸ | TNNC1 | P63316 | 1/20 | 0.32 |
| ▸ | CERS2 | Q96G23 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL331681 | 0.98 | LIPG (0.40) | LIPGTLR8CYP3A4CYP2D6CYP2C9 | |
| Bromide SCHEMBL3386923 | 0.97 | LIPG (0.39) | LIPGTLR8CYP3A4CYP2D6CYP2C9 | |
| Water SCHEMBL187670 | 0.97 | LIPG (0.39) | LIPGTLR8CYP3A4CYP2D6CYP2C9 | |
| Iodide SCHEMBL21808913 | 0.97 | LIPG (0.39) | LIPGTLR8CYP3A4CYP2D6CYP2C9 | |
| Hydrochloric Acid SCHEMBL28845901 | 0.92 | LIPG (0.45) | LIPGTLR8S1PR1CYSLTR2CYSLTR1 | |
| Bicarbonate SCHEMBL28525416 | 0.91 | CYSLTR2 (0.41) | LIPGCYSLTR2CYSLTR1 | |
| Hydrochloric Acid SCHEMBL8591558 | 0.90 | LIPG (0.47) | LIPGTLR8S1PR1CYSLTR2CYSLTR1 | |
| Hydrochloric Acid SCHEMBL3387556 | 0.90 | LIPG (0.47) | LIPGTLR8S1PR1CYSLTR2CYSLTR1 | |
| Hydrochloric Acid SCHEMBL2059992 | 0.90 | LIPG (0.47) | LIPGTLR8S1PR1CYSLTR2CYSLTR1 | |
| Hydrochloric Acid SCHEMBL15811749 | 0.90 | LIPG (0.47) | LIPGTLR8S1PR1CYSLTR2CYSLTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 951 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119506974-A | Method for recovering tungsten carbide and cobalt from waste tungsten-cobalt hard alloy | 赣州有色冶金研究所有限公司 | 2025-02-25 | — | — | CN | claimed |
| CN-117986239-A | Irbesartan preparation method | 珠海润都制药股份有限公司 | 2024-05-07 | — | — | CN | claimed |
| CN-117623912-A | Method for extracting crocetin by deep eutectic solvent conversion | 北京工商大学 | 2024-03-01 | — | — | CN | claimed |
| CN-114213286-B | Synthetic method of urea derivative | 湖北文理学院 | 2022-12-30 | — | — | CN | claimed |
| CN-114249896-A | Allyl-terminated aryl sulfone ether polymer and preparation method thereof | 兰溪聪普新材料有限公司 | 2022-03-29 | — | — | CN | claimed |
| CN-114213286-A | Synthetic method of urea derivative | 湖北文理学院 | 2022-03-22 | — | — | CN | claimed |
| CN-109503693-B | Process for synthesizing Aramchol by using cholic acid as raw material | 合肥工业大学 | 2021-04-06 | — | — | CN | claimed |
| US-8859769-B2 | Processes for preparing ticagrelor intermediate, 4,6-dichloro-5-nitro-2-(propylthio)pyrimidine | ACTAVIS GROUP PTC EHF (IS) | 2014-10-14 | — | — | US | claimed |
| EP-1988109-B1 | POLYMERIZABLE COMPOSITION FOR POLYTHIOURETHANE OPTICAL MATERIAL | MITSUI CHEMICALS INC (JP) | 2013-05-29 | — | — | EP | claimed |
| US-20130072682-A1 | PROCESS FOR PREPARING VARENICLINE, VARENICLINE INTERMEDIATES, AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | ACTAVIS GROUP PTC EHF (IS) | 2013-03-21 | — | — | US | claimed |
| US-20050043499-A1 | Ketone-aldehyde resins having low water content, high thermal stability and yellowing resistance | DEGUSSA AG (DE) | 2005-02-24 | — | — | US | claimed |
| US-20050010016-A1 | Resins based on ketones and aldehydes, having improved solubility properties and low color numbers | DEGUSSA AG (DE) | 2005-01-13 | — | — | US | claimed |
| US-6465576-B1 | Fluoroelastomer compositions and articles made therefrom | DYNEON LLC | 2002-10-15 | — | — | US | claimed |
| EP-0833857-B1 | IMPROVED SCORCH SAFETY OF CURABLE FLUOROELASTOMER COMPOSITIONS | DYNEON LLC (US) | 2002-07-24 | — | — | EP | claimed |
| EP-1194462-A1 | FLUOROELASTOMER COMPOSITIONS AND ARTICLES MADE THEREFROM | Dyneon LLC (US) | 2002-04-10 | — | — | EP | claimed |
| WO-2001002448-A1 | FLUOROELASTOMER COMPOSITIONS AND ARTICLES MADE THEREFROM | DYNEON LLC (US) | 2001-01-11 | — | — | WO | claimed |
| US-5756588-A | CURABLE COMPOSITION COMPRISING FLUOROPOLYMER, AROMATIC POLYHYDROXY CROSSLINKING AGENT, ORGANO-ONIUM COMPOUND, MONOHYDROXYFUNCTIONAL PHENOL CAPABLE OF DELAYING POST-COMPOUNDING INITIATION | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1998-05-26 | — | — | US | claimed |
| EP-0833857-A1 | IMPROVED SCORCH SAFETY OF CURABLE FLUOROELASTOMER COMPOSITIONS | DYNEON LLC (US) | 1998-04-08 | — | — | EP | claimed |
| WO-1997000906-A1 | IMPROVED SCORCH SAFETY OF CURABLE FLUOROELASTOMER COMPOSITIONS | DYNEON LLC (US) | 1997-01-09 | — | — | WO | claimed |
| US-4594467-A | DEHYDROBROMINATING ALPH-BROMO-3,5-DICHLORO CUMENE WITH ALKALI METAL HYDROXIDE IN PRESENCE OF PHASE TRANSFER CATALYST | BAYER AKTIENGESELLSCHAFT (DE) | 1986-06-10 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130072682-A1 | PROCESS FOR PREPARING VARENICLINE, VARENICLINE INTERMEDIATES, AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | TET2, NOX4, CYP3A7 | S1PR1 1118/4885SLC6A2 357/4885SLC6A4 861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.